Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A. Eyre, Graham P. Collins, Harriet S. Walter et al.|Haematologica|2018Cited by 137
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic reviewToby A. Eyre, Graham P. Collins, Faouzi Djebbari et al.|Haematologica|2019Cited by 70
<scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A. Eyre, Anna Schuh, Christopher P. Fox et al.|British Journal of Haematology|2016Cited by 66
Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicityToby A. Eyre, Chris S.R Hatton, Amy A. Kirkwood et al.|British Journal of Haematology|2019Cited by 65
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b StudyNirav N. Shah, Talha Munir, Zulfa Omer et al.|Blood|2024Cited by 27